STOCK TITAN

BIO-TECHNE DECLARES DIVIDEND

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2024. The dividend will be payable on August 30, 2024, to shareholders of record as of August 19, 2024. This decision was made by the company's Board of Directors, who will consider future cash dividends on a quarterly basis.

Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics. With a diverse portfolio of thousands of products, the company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide.

Loading...
Loading translation...

Positive

  • Declared quarterly dividend of $0.08 per share
  • Generated approximately $1.2 billion in net sales for fiscal 2024
  • Maintains a large product portfolio serving research and clinical diagnostic markets

Negative

  • None.

News Market Reaction – TECH

-9.51%
1 alert
-9.51% News Effect

On the day this news was published, TECH declined 9.51%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com.

Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact: 

David Clair, Vice President, Investor Relations & Corporate Development


David.Clair@bio-techne.com


612-656-4416

BT Logo (PRNewsfoto/Bio-Techne Corporation)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302216347.html

SOURCE Bio-Techne Corporation

FAQ

What is the amount of Bio-Techne's (TECH) quarterly dividend for Q2 2024?

Bio-Techne (NASDAQ: TECH) has declared a quarterly dividend of $0.08 per share for the quarter ended June 30, 2024.

When will Bio-Techne (TECH) pay its Q2 2024 dividend?

Bio-Techne will pay the quarterly dividend on August 30, 2024, to shareholders of record as of August 19, 2024.

What was Bio-Techne's (TECH) net sales for fiscal 2024?

Bio-Techne reported approximately $1.2 billion in net sales for fiscal 2024.

How many employees does Bio-Techne (TECH) have globally?

Bio-Techne has approximately 3,100 employees worldwide.